Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.

ABSTRACT: Inflammation is a hallmark of cancer¹. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across malignancies and therapeutic modalities^2-5. Whether myeloid inflammation drives progression of prostate cancer in humans remain unclear. Here we show that inhibition of myeloid chemotaxis can reduce tumour-elicited myeloid inflammation and reverse therapy resistance in a subset of patients with metastatic castration-resistant prostate cancer (CRPC). We show that a higher blood neutrophil-to-lymphocyte ratio reflects tumour myeloid infiltration and tumour expression of senescence-associated mRNA species, including those that encode myeloid-chemoattracting

SUBMITTER: Guo C 

PROVIDER: S-EPMC10686834 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature